Catalent Pharma Solutions’ Post

Our Chief Quality Officer, Rashida Najmi, shares her insights on advancing the therapeutic development of Antibody Drug Conjugates (ADCs) with a strong focus on #quality in the latest issue of Pharma Horizon – Biologics report by European Pharmaceutical Review. In her article, she explores the current landscape, key challenges, and innovative solutions in ADC development. To read, head over to page 6 on this link: https://lnkd.in/eX-aqeJf #PPLInsights

Pharmaceutical Technology Europe May 2024: Biologics on Target for the Future A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics. View the issue here: https://lnkd.in/e-mQF9yq

Prof. Chinmay Ghoroi, PhD recently delivered an insightful talk at the 3rd conference on Nanomechanics for Pharmaceutical Applications (NPA 2023), discussing the critical role of nano-scale contact in processing fine pharmaceutical drug particles. #Nanotechnology #PharmaceuticalEngineering #NPA2023

Accelerate speed-to-market for heat sensitive drugs, including biologics. Monoclonal antibodies and other heat-sensitive biopharmaceuticals may rely on lyophilization to dry compounds without heat. Lyophilization is a complex process that poses tech transfer and scale-up challenges. Here’s how data driven approaches can accelerate process optimization and shorten time-to-market. https://bit.ly/42bKHcp

The European Union In Vitro Diagnostics Regulation (IVDR) is changing the landscape of diagnostic provision within the EU, but what are the implications to both diagnostic providers and the pharmaceutical industry as a whole? Our latest blog post with Almac Group dives into this new regulation, it's background, challenges & what you need to know going forward. https://lnkd.in/gfkkgg2V

Revolutionizing Healthcare: Biologics CDMOs Set to Soar to $27 Billion by 2028- Insights from BCC Research: Biologics Contract Development and Manufacturing Organizations (CDMOs) have emerged as pivotal players in the dynamic landscape of the global pharmaceutical industry. Fueled by rapid advancements in biotechnology, these specialized entities offer end-to-end solutions, from development to...

📌India Med Today has featured an article titled "The Blockbuster Biosimilar Drugs" highlighting the rise of biosimilar drugs in India as affordable alternatives to biologics. Sridevi Khambhampaty, VP – Biopharmaceutical Development, Syngene International shares insights on the safety and efficacy of biosimilar drugs compared to biologics, emphasizing their validation through extensive clinical studies. Sridevi also highlights the critical need for transparency in publishing comparability data and clinical experiences of Indian biosimilar manufacturers and clinicians. To read the full article, visit the link in the comments section🔗 #Syngene #biosimilardrugs #CDMO

Pharmaceutical Technology May 2024: Biologics on Target for the Future A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics. Read our issue here: https://lnkd.in/eTDWbhHY

In the world of medicine, we’re constantly seeking ways to improve patient care while managing costs. Enter biosimilars – a revolutionary class of drugs that’s shaking up the pharmaceutical industry. But what exactly are biosimilars, and how do they stack up against their more expensive counterparts? Let’s dive into this fascinating topic and explore why some biosimilars are proving to be just as effective as pricey biologics. https://lnkd.in/eRamt4mU

Check out our latest blog on Scientist.Com